Aesthetic treatments regulation debate reaches Parliament

The Government has admitted shortcomings in non-surgical cosmetic treatment regulation reform post-Keogh review. In a parliamentary debate held on February 12 in Westminster Hall, Jackie Doyle-Price, parliamentary under-secretary of state for mental health and suicide prevention, admitted that the Government had “some way to go” to making sure that all those administering non-surgical treatments such as injectables are performing treatments to high standards.

In January, Prime Minister Theresa May addressed regulation issues during Prime Minister’s Questions. Questioned by Alberto Costa, Conservative MP for South Leicestershire, on the topic, May replied: “We recognise that this growth in non-surgical treatments does increase the need for consumer protection. We are currently working with stakeholders to strengthen the regulation and we are committed to increasing the safety of these procedures in a number of ways.”

Her comments were echoed during the February debate, when Doyle-Price added: “In wishing to regulate this sector we do not want to undermine its dynamism and competitiveness. What we really need to do is make sure that consumers are properly educated so that they can make informed choices about where they seek treatments.”

While she didn’t respond directly to Costa’s call for “the Government to at least consider setting out a cohesive and comprehensive plan to properly regulate the non-surgical cosmetic industry”, Doyle-Price did remind those in attendance of what has been done since 2013’s Keogh review, including the training and qualification framework; and the formation of the Joint Council for Cosmetic Practitioners (JCCP): “We need to work closely with the JCCP so we can develop hallmarks for people to look for so they can be sure they’re obtaining a treatment from a regulated practitioner,” she said. Doyle-Price also reiterated that as of May 2020, all dermal fillers will be regulated as medical devices under the Medicines and Healthcare Products Regulatory Agency. However, this doesn’t mean that the products will be prescription-only.